The study focuses on diseases targeted for pancreaticoduodenectomy. pancreaticoduodenectomy
Conditions
Interventions
Oral administration of kestose.
Administration, Oral
Sponsors
Takahara Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient who will undergo pancreaticodudodenectomy at Fujita Health University hospital with sufficient understanding of the study and having written informed consent. The patient age is between 20 and 90.
Exclusion criteria
Exclusion criteria: Patients deemed unsuitable for this study by the principal investigator or co-investigators will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum albumin level of 24 weeks after the operation | — |
Secondary
| Measure | Time frame |
|---|---|
| The manifestation of fatty liver Changes in glucose tolerance The occupancy rate of beneficial microbiota in the oral and intestinal microbiota The transition of nutritional status and sarcopenia 1 year and 3 years after surgery Dose intensity of postoperative chemotherapy Improvement in nutritional status 6, 12, and 24 weeks after kestose administration as indicated by biological marker scores, including changes in muscle mass evaluated using Inbody, CT, and changes in blood biochemical test values (albumin levels, total lymphocyte count, VitD3, Fe, UIBC, Zn, Mg, ferritin, transferrin, total cholesterol levels, LDL cholesterol levels, HDL cholesterol levels, triglycerides, blood glucose levels, HbA1c, cholinesterase) Prognostic Nutritional Index (PNI) | — |
Contacts
Public ContactYuichiro Uchida
Department of Surgery, Fujita Health University
Outcome results
None listed